In this article, we illustrate the application of difference in-gel electrophoresis for the proteomic analysis of dystrophic skeletal muscle. The mdx diaphragm was used as a tissue model of dystrophinopathy. Two-dimensional gel electrophoresis is a widely employed protein separation method in proteomic investigations. Although two-dimensional gels usually underestimate the cellular presence of very high molecular mass proteins, integral membrane proteins and low copy number proteins, this method is extremely powerful in the comprehensive analysis of contractile proteins, metabolic enzymes, structural proteins and molecular chaperones. This gives rise to two-dimensional gel electrophoretic separation as the method of choice for studying contractile tissues in health and disease. For comparative studies, fluorescence difference in-gel electrophoresis has been shown to provide an excellent biomarker discovery tool. Since aged diaphragm fibres from the mdx mouse model of Duchenne muscular dystrophy closely resemble the human pathology, we have carried out a mass spectrometry-based comparison of the naturally aged diaphragm versus the senescent dystrophic diaphragm. The proteomic comparison of wild type versus mdx diaphragm resulted in the identification of 84 altered protein species. Novel molecular insights into dystrophic changes suggest increased cellular stress, impaired calcium buffering, cytostructural alterations and disturbances of mitochondrial metabolism in dystrophin-deficient muscle tissue.
References
[1]
Isfort, R.J. Proteomic analysis of striated muscle. J. Chromatogr. B 2002, 771, 155–165, doi:10.1016/S1570-0232(02)00056-9.
[2]
Ohlendieck, K. Proteomics of skeletal muscle differentiation, neuromuscular disorders and fiber aging. Expert Rev. Proteomics 2010, 7, 283–296, doi:10.1586/epr.10.2.
[3]
Gelfi, C.; Vasso, M.; Cerretelli, P. Diversity of human skeletal muscle in health and disease: Contribution of proteomics. J. Proteomics 2011, 74, 774–795, doi:10.1016/j.jprot.2011.02.028.
[4]
Ohlendieck, K. Proteomic identification of biomarkers of skeletal muscle disorders. Biomark. Med. 2013, 7, 169–186, doi:10.2217/bmm.12.96.
[5]
Chevalier, F. Highlights on the capacities of “Gel-based” proteomics. Proteome Sci. 2010, 8, 23, doi:10.1186/1477-5956-8-23.
[6]
Rabilloud, T.; Chevallet, M.; Luche, S.; Lelong, C. Two-dimensional gel electrophoresis in proteomics: Past, present and future. J. Proteomics 2010, 73, 2064–2077, doi:10.1016/j.jprot.2010.05.016.
[7]
Westermeier, R.; G？rg, A. Two-dimensional electrophoresis in proteomics. Methods Biochem. Anal. 2011, 54, 411–439, doi:10.1002/9780470939932.ch17.
[8]
Ohlendieck, K. Skeletal muscle proteomics: Current approaches, technical challenges and emerging techniques. Skelet. Muscle 2011, 1, 6, doi:10.1186/2044-5040-1-6.
[9]
Parker, K.C.; Walsh, R.J.; Salajegheh, M.; Amato, A.A.; Krastins, B.; Sarracino, D.A.; Greenberg, S.A. Characterization of human skeletal muscle biopsy samples using shotgun proteomics. J. Proteome Res. 2009, 8, 3265–3277, doi:10.1021/pr800873q.
[10]
Holland, A.; Ohlendieck, K. Proteomic profiling of the contractile apparatus from skeletal muscle. Expert Rev. Proteomics 2013, 10, 239–257, doi:10.1586/epr.13.20.
[11]
Maughan, D.W.; Henkin, J.A.; Vigoreaux, J.O. Concentrations of glycolytic enzymes and other cytosolic proteins in the diffusible fraction of a vertebrate muscle proteome. Mol. Cell. Proteomics 2005, 4, 1541–1549, doi:10.1074/mcp.M500053-MCP200.
[12]
H？jlund, K.; Yi, Z.; Hwang, H.; Bowen, B.; Lefort, N.; Flynn, C.R.; Langlais, P.; Weintraub, S.T.; Mandarino, L.J. Characterization of the human skeletal muscle proteome by one-dimensional gel electrophoresis and HPLC-ESI-MS/MS. Mol. Cell. Proteomics 2008, 7, 257–267.
Choi, Y.S. Reaching for the deep proteome: Recent nano liquid chromatography coupled with tandem mass spectrometry-based studies on the deep proteome. Arch. Pharm. Res. 2012, 35, 1861–1870, doi:10.1007/s12272-012-1102-y.
[15]
Hamano, K.; Takeya, T.; Iwasaki, N.; Okoshi, N.; Fukubayashi, T.; Kirinoki, M.; Yao, Y.; Hirabayashi, T.; Takita, H. Analysis of dystrophin in muscular diseases by two-dimensional gel electrophoresis using agarose gels in the first dimension. Acta Neurol. Belg. 1996, 96, 102–107.
[16]
Oh-Ishi, M.; Maeda, T. Disease proteomics of high-molecular-mass proteins by two-dimensional gel electrophoresis with agarose gels in the first dimension (Agarose 2-DE). J. Chromatogr. B 2007, 849, 211–222, doi:10.1016/j.jchromb.2006.10.064.
[17]
Reisinger, V.; Eichacker, L.A. Isolation of membrane protein complexes by blue native electrophoresis. Methods Mol. Biol. 2008, 424, 423–431, doi:10.1007/978-1-60327-064-9_33.
[18]
Wittig, I.; Sch？gger, H. Native electrophoretic techniques to identify protein-protein interactions. Proteomics 2009, 9, 5214–5223, doi:10.1002/pmic.200900151.
[19]
Froemming, G.R.; Murray, B.E.; Ohlendieck, K. Self-aggregation of triadin in the sarcoplasmic reticulum of rabbit skeletal muscle. Biochim. Biophys. Acta 1999, 1418, 197–205, doi:10.1016/S0005-2736(99)00024-3.
[20]
Brennan, J.P.; Wait, R.; Begum, S.; Bell, J.R.; Dunn, M.J.; Eaton, P. Detection and mapping of widespread intermolecular protein disulfide formation during cardiac oxidative stress using proteomics with diagonal electrophoresis. J. Biol. Chem. 2004, 279, 41352–41360.
[21]
Fraterman, S.; Zeiger, U.; Khurana, T.S.; Rubinstein, N.A.; Wilm, M. Combination of peptide OFFGEL fractionation and label-free quantitation facilitated proteomics profiling of extraocular muscle. Proteomics 2007, 7, 3404–3416, doi:10.1002/pmic.200700382.
[22]
Gannon, J.; Ohlendieck, K. Subproteomic analysis of basic proteins in aged skeletal muscle following offgel pre-fractionation. Mol. Med. Rep. 2012, 5, 993–1000.
[23]
Staunton, L.; Ohlendieck, K. Mass spectrometric characterization of the sarcoplasmic reticulum from rabbit skeletal muscle by on-membrane digestion. Protein Pept. Lett. 2012, 19, 252–263, doi:10.2174/092986612799363208.
[24]
Ohlendieck, K. On-membrane digestion technology for muscle proteomics. J. Membr. Sep. Technol. 2013, 2, 1–12.
[25]
Guevel, L.; Lavoie, J.R.; Perez-Iratxeta, C.; Rouger, K.; Dubreil, L.; Feron, M.; Talon, S.; Brand, M.; Megeney, L.A. Quantitative proteomic analysis of dystrophic dog muscle. J. Proteome Res. 2011, 10, 2465–2478, doi:10.1021/pr2001385.
[26]
Rayavarapu, S.; Coley, W.; Cakir, E.; Jahnke, V.; Takeda, S.; Aoki, Y.; Grodish-Dressman, H.; Jaiswal, J.K.; Hoffman, E.P.; Brown, K.J.; et al. Identification of disease specific pathways using in vivo SILAC proteomics in dystrophin deficient mdx mouse. Mol. Cell. Proteomics 2013, 12, 1061–1073, doi:10.1074/mcp.M112.023127.
[27]
Duguez, S.; Duddy, W.; Johnston, H.; Lainé, J.; Le Bihan, M.C.; Brown, K.J.; Bigot, A.; Hathout, Y.; Butler-Browne, G.; Partridge, T. Dystrophin deficiency leads to disturbance of LAMP1-vesicle-associated protein secretion. Cell. Mol. Life Sci. 2013, 70, 2159–2174, doi:10.1007/s00018-012-1248-2.
[28]
Malm, C.; Hadrevi, J.; Bergstr？m, S.A.; Pedrosa-Domell？f, F.; Antti, H.; Svensson, M.; Fr？ngsmyr, L. Evaluation of 2-D DIGE for skeletal muscle: Protocol and repeatability. Scand. J. Clin. Lab. Invest. 2008, 68, 793–800, doi:10.1080/00365510802277464.
[29]
Unlü, M.; Morgan, M.E.; Minden, J.S. Difference gel electrophoresis: A single gel method for detecting changes in protein extracts. Electrophoresis 1997, 18, 2071–2077, doi:10.1002/elps.1150181133.
[30]
Alban, A.; David, S.O.; Bjorkesten, L.; Andersson, C.; Sloge, E.; Lewis, S.; Currie, I. A novel experimental design for comparative two-dimensional gel analysis: Two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 2003, 3, 36–44, doi:10.1002/pmic.200390006.
[31]
Viswanathan, S.; Unlü, M.; Minden, J.S. Two-dimensional difference gel electrophoresis. Nat. Protoc. 2006, 1, 1351–1358, doi:10.1038/nprot.2006.234.
Tonge, R.; Shaw, J.; Middleton, B.; Rowlinson, R.; Rayner, S.; Young, J.; Pognan, F.; Hawkins, E.; Currie, I.; Davison, M. Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics 2001, 1, 377–396, doi:10.1002/1615-9861(200103)1:3<377::AID-PROT377>3.0.CO;2-6.
[34]
Marouga, R.; David, S.; Hawkins, E. The development of the DIGE system: 2D fluorescence difference gel analysis technology. Anal. Bioanal. Chem. 2005, 382, 669–678, doi:10.1007/s00216-005-3126-3.
[35]
Karp, N.A.; Kreil, D.P.; Lilley, K.S. Determining a significant change in protein expression with DeCyder during a pair-wise comparison using two-dimensional difference gel electrophoresis. Proteomics 2004, 4, 1421–1432, doi:10.1002/pmic.200300681.
[36]
Karp, N.A.; Lilley, K.S. Maximising sensitivity for detecting changes in protein expression: Experimental design using minimal CyDyes. Proteomics 2005, 5, 3105–3115, doi:10.1002/pmic.200500083.
[37]
Doran, P.; Martin, G.; Dowling, P.; Jockusch, H.; Ohlendieck, K. Proteome analysis of the dystrophin-deficient MDX diaphragm reveals a drastic increase in the heat shock protein cvHSP. Proteomics 2006, 6, 4610–4621, doi:10.1002/pmic.200600082.
[38]
Corzett, T.H.; Fodor, I.K.; Choi, M.W.; Walsworth, V.L.; Chromy, B.A.; Turteltaub, K.W.; McCutchen-Maloney, S.L. Statistical analysis of the experimental variation in the proteomic characterization of human plasma by two-dimensional difference gel electrophoresis. J. Proteome Res. 2006, 5, 2611–2619, doi:10.1021/pr060100p.
[39]
Guenet, J.L. Animal models of human genetic diseases: Do they need to be faithful to be useful? Mol. Genet. Genomics 2011, 286, 1–20, doi:10.1007/s00438-011-0627-y.
[40]
Vainzof, M.; Ayub-Guerrieri, D.; Onofre, P.C.; Martins, P.C.; Lopes, V.F.; Zilberztajn, D.; Maia, L.S.; Sell, K.; Yamamoto, L.U. Animal models for genetic neuromuscular diseases. J. Mol. Neurosci. 2008, 34, 241–248.
Koenig, M.; Hoffman, E.P.; Bertelson, C.J.; Monaco, A.P.; Feener, C.; Kunkel, L.M. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 1987, 50, 509–517.
[43]
Nakamura, A.; Takeda, S. Mammalian models of Duchenne Muscular Dystrophy: Pathological characteristics and therapeutic applications. J. Biomed. Biotechnol. 2011, 2011. Article ID 184393.
Banks, G.B.; Chamberlain, J.S. The value of mammalian models for Duchenne muscular dystrophy in developing therapeutic strategies. Curr. Top. Dev. Biol. 2008, 84, 431–453, doi:10.1016/S0070-2153(08)00609-1.
[46]
Kornegay, J.N.; Bogan, J.R.; Bogan, D.J.; Childers, M.K.; Li, J.; Nghiem, P.; Detwiler, D.A.; Larsen, C.A.; Grange, R.W.; Bhavaraju-Sanka, R.K.; et al. Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies. Mamm. Genome 2012, 23, 85–108, doi:10.1007/s00335-011-9382-y.
[47]
Ge, Y.; Molloy, M.P.; Chamberlain, J.S.; Andrews, P.C. Proteomic analysis of mdx skeletal muscle: Great reduction of adenylate kinase 1 expression and enzymatic activity. Proteomics 2003, 3, 1895–1903, doi:10.1002/pmic.200300561.
[48]
Holland, A.; Dowling, P.; Zweyer, M.; Swandulla, D.; Henry, M.; Clynes, M.; Ohlendieck, K. Proteomic profiling of cardiomyopathic tissue from the aged mdx model of Duchenne muscular dystrophy reveals a drastic decrease in laminin, nidogen and annexin. Proteomics 2013, 13, 2312–2323, doi:10.1002/pmic.201200578.
[49]
Doran, P.; Wilton, S.D.; Fletcher, S.; Ohlendieck, K. Proteomic profiling of antisense-induced exon skipping reveals reversal of pathobiochemical abnormalities in dystrophic mdx diaphragm. Proteomics 2009, 9, 671–685, doi:10.1002/pmic.200800441.
[50]
Lewis, C.; Carberry, S.; Ohlendieck, K. Proteomic profiling of x-linked muscular dystrophy. J. Muscle Res. Cell Motil. 2009, 30, 267–269, doi:10.1007/s10974-009-9197-6.
[51]
Lefaucheur, J.P.; Pastoret, C.; Sebille, A. Phenotype of dystrophinopathy in old mdx mice. Anat. Rec. 1995, 242, 70–76, doi:10.1002/ar.1092420109.
[52]
Head, S.I. Branched fibres in old dystrophic mdx muscle are associated with mechanical weakening of the sarcolemma, abnormal Ca2+ transients and a breakdown of Ca2+ homeostasis during fatigue. Exp. Physiol. 2010, 95, 641–656, doi:10.1113/expphysiol.2009.052019.
[53]
Chamberlain, J.S.; Metzger, J.; Reyes, M.; Townsend, D.; Faulkner, J.A. Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. FASEB J. 2007, 21, 2195–2204, doi:10.1096/fj.06-7353com.
[54]
Mouisel, E.; Vignaud, A.; Hourde, C.; Butler-Browne, G.; Ferry, A. Muscle weakness and atrophy are associated with decreased regenerative capacity and changes in mTOR signaling in skeletal muscles of venerable (18-24-month-old) dystrophic mdx mice. Muscle Nerve 2010, 41, 809–818, doi:10.1002/mus.21624.
[55]
Carberry, S.; Zweyer, M.; Swandulla, D.; Ohlendieck, K. Proteomics reveals drastic increase of extracellular matrix proteins collagen and dermatopontin in aged mdx diaphragm muscle. Int. J. Mol. Med. 2012, 30, 229–234.
[56]
Carberry, S.; Zweyer, M.; Swandulla, D.; Ohlendieck, K. Profiling of age-related changes in the tibialis anterior muscle proteome of the mdx mouse model of dystrophinopathy. J. Biomed. Biotechnol. 2012, 2012, 691641.
[57]
Sicinski, P.; Geng, Y.; Ryder-Cook, A.S.; Barnard, E.A.; Darlison, M.G.; Barnard, P.J. The molecular basis of muscular dystrophy in the mdx mouse: A point mutation. Science 1989, 244, 1578–1580.
[58]
Stedman, H.H.; Sweeney, H.L.; Shrager, J.B.; Maguire, H.C.; Panettieri, R.A.; Petrof, B.; Narusawa, M.; Leferovich, J.M.; Sladky, J.T.; Kell, A.M. The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 1991, 352, 536–539, doi:10.1038/352536a0.
[59]
Staunton, L.; Jockusch, H.; Ohlendieck, K. Proteomic analysis of muscle affected by motor neuron degeneration: The wobbler mouse model of amyotrophic lateral sclerosis. Biochem. Biophys.Res. Commun. 2011, 406, 595–600, doi:10.1016/j.bbrc.2011.02.099.
[60]
O’Connell, K.; Ohlendieck, K. Proteomic DIGE analysis of the mitochondria-enriched fraction from aged rat skeletal muscle. Proteomics 2009, 9, 5509–5524, doi:10.1002/pmic.200900472.
[61]
Kang, Y.; Techanukul, T.; Mantalaris, A.; Nagy, J.M. Comparison of three commercially available DIGE analysis software packages: Minimal user intervention in gel-based proteomics. J. Proteome Res. 2009, 8, 1077–1084.
[62]
Carberry, S.; Ohlendieck, K. Gel electrophoresis-based proteomics of senescent tissues. Methods Mol. Biol. 1048, 229–246.
[63]
Staunton, L.; Jockusch, H.; Wiegand, C.; Albrecht, T.; Ohlendieck, K. Identification of secondary effects of hyperexcitability by proteomic profiling of myotonic mouse muscle. Mol. Biosyst. 2011, 7, 2480–2489, doi:10.1039/c1mb05043e.
[64]
PANTHER Gene List Analysis. Available online: http://pantherdb.org/ (accessed on 15 November 2013).
[65]
Mi, H.; Muruganujan, A.; Thomas, P.D. PANTHER in 2013: Modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees. Nucleic Acids Res. 2013, 41, D377–D386, doi:10.1093/nar/gks1118.
[66]
STRING Functional Protein Association Network. Available online: http://string-db.org/ (accessed on 17 November 2013).
[67]
Franceschini, A.; Szklarczyk, D.; Frankild, S.; Kuhn, M.; Simonovic, M.; Roth, A.; Lin, J.; Minguez, P.; Bork, P.; von Mering, C.; et al. STRING v9.1: Protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 2013, 41, D808–D815, doi:10.1093/nar/gks1094.
[68]
Staunton, L.; Zweyer, M.; Swandulla, D.; Ohlendieck, K. Mass spectrometry-based proteomic analysis of middle-aged vs. aged vastus lateralis reveals increased levels of carbonic anhydrase isoform 3 in senescent human skeletal muscle. Int. J. Mol. Med. 2012, 30, 723–733.
[69]
Holland, A.; Carberry, S.; Ohlendieck, K. Proteomics of the dystrophin-glycoprotein complex and dystrophinopathy. Curr. Protein Pep. Sci. 2013. in press.
[70]
Culligan, K.; Banville, N.; Dowling, P.; Ohlendieck, K. Drastic reduction of calsequestrin-like proteins and impaired calcium binding in dystrophic mdx muscle. J. Appl. Physiol. 2002, 92, 435–445.
Pontén, F.; Schwenk, J.M.; Asplund, A.; Edqvist, P.H. The Human Protein Atlas as a proteomic resource for biomarker discovery. J. Intern. Med. 2011, 270, 428–446, doi:10.1111/j.1365-2796.2011.02427.x.
[73]
Theodoridis, G.A.; Gika, H.G.; Want, E.J.; Wilson, I.D. Liquid chromatography-mass spectrometry based global metabolite profiling: A review. Anal. Chim. Acta 2012, 711, 7–16, doi:10.1016/j.aca.2011.09.042.
[74]
Cox, J.; Mann, M. Quantitative, high-resolution proteomics for data-driven systems biology. Annu. Rev. Biochem. 2011, 80, 273–299.
[75]
Stastna, M.; van Eyk, J.E. Secreted proteins as a fundamental source for biomarker discovery. Proteomics 2012, 12, 722–735, doi:10.1002/pmic.201100346.
[76]
Mallick, P.; Kuster, B. Proteomics: A pragmatic perspective. Nat. Biotechnol. 2010, 28, 695–709, doi:10.1038/nbt.1658.
[77]
Graham, K.M.; Singh, R.; Millman, G.; Malnassy, G.; Gatti, F.; Bruemmer, K.; Stefanski, C.; Curtis, H.; Sesti, J.; Carlson, C.G. Excessive collagen accumulation in dystrophic (mdx) respiratory musculature is independent of enhanced activation of the NF-kappaB pathway. J. Neurol. Sci. 2010, 294, 43–50.
[78]
Wang, J.; Pantopoulos, K. Regulation of cellular iron metabolism. Biochem. J. 2011, 434, 365–381, doi:10.1042/BJ20101825.
[79]
Kuznetsov, A.V.; Winkler, K.; Wiedemann, F.R.; von Bossanyi, P.; Dietzmann, K.; Kunz, W.S. Impaired mitochondrial oxidative phosphorylation in skeletal muscle of the dystrophin-deficient mdx mouse. Mol. Cell. Biochem. 1998, 183, 87–96, doi:10.1023/A:1006868130002.
[80]
Percival, J.M.; Siegel, M.P.; Knowels, G.; Marcinek, D.J. Defects in mitochondrial localization and ATP synthesis in the mdx mouse model of Duchenne muscular dystrophy are not alleviated by PDE5 inhibition. Hum. Mol. Genet. 2013, 22, 153–167.
[81]
Doran, P.; Dowling, P.; Donoghue, P.; Buffini, M.; Ohlendieck, K. Reduced expression of regucalcin in young and aged mdx diaphragm indicates abnormal cytosolic calcium handling in dystrophin-deficient muscle. Biochim. Biophys. Acta 2006, 1764, 773–785.
[82]
Doran, P.; Dowling, P.; Lohan, J.; McDonnell, K.; Poetsch, S.; Ohlendieck, K. Subproteomics analysis of Ca2+-binding proteins demonstrates decreased calsequestrin expression in dystrophic mouse skeletal muscle. Eur. J. Biochem. 2004, 271, 3943–3952.
[83]
Carberry, S.; Brinkmeier, H.; Zhang, Y.; Winkler, C.K.; Ohlendieck, K. Comparative proteomic profiling of soleus, extensor digitorum longus, flexor digitorum brevis and interosseus muscle from the mdx mouse model of Duchenne muscular dystrophy. Int. J. Mol. Med. 2013, 32, 544–556.
[84]
Gardan-Salmon, D.; Dixon, J.M.; Lonergan, S.M.; Selsby, J.T. Proteomic assessment of the acute phase of dystrophin deficiency in mdx mice. Eur. J. Appl. Physiol. 2011, 111, 2763–2773, doi:10.1007/s00421-011-1906-3.
[85]
Carberry, S.; Zweyer, M.; Swandulla, D.; Ohlendieck, K. Comparative proteomic analysis of the contractile protein-depleted fraction from normal versus dystrophic skeletal muscle. Anal. Biochem. 2013, doi:10.1016/j.ab.2013.08.004.
